Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110]
In development
Reference number: GID-TA11023
Expected publication date: TBC
Please note that following on from advice received from the company this appraisal has been rescheduled. We now anticipate that the appraisal will begin during mid-July 2024 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid-September 2024.